Remaining leukemic cells that persist in the body of patients after treatment are called minimal residual disease (MRD (Minimal residual disease)). These cells are very hard to detect and are the major cause of relapses in these patients. It is believed that these cells were able to resist initial therapy by developing drug resistance(s).

Dr. Eckert's lab is in charge of the molecular genetics diagnostics laboratory for MRD (Minimal residual disease) diagnostic in close collaboration with the current ALL-REZ BFM study conducted with the Pediatric Hematology and Oncology department at the Charité.

Publications (for a complete list, click here)